Shire has announced that the FDA has approved Once-Daily INTUNIV (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17.
INTUNIV, the first nonscheduled alpha-2A receptor agonist indicated for Attention-Deficit/Hyperactivity Disorder (ADHD) demonstrated improvement in a range of ADHD symptoms that can be disruptive, such as inattention, arguing with adults, hyperactivity, impulsivity, and losing one's temper.
What's interesting is that INTUNIV is not a controlled substance by the DEA and has no known potential for abuse or dependence. Don't get this drug confused with guaifenesin (which is found in many common cold medicines). Look at how similar they are:
Anti-Tuss, Bidex, Breonesin, Duratuss G, Fenesin, Ganidin NR, GG 200 NR, Guaifenesin LA, Guaifenex G, Guaifenex LA, Humibid L.A., Humibid Pediatric, Liquibid, Muco-Fen 1200, Muco-Fen 800, Muco-Fen LA, Naldecon-EX Senior, Organidin NR, Pneumomist, Q-Bid LA, Robitussin, Scot-Tussin, Touro EX